Petersen KU, Schmalix W, Pesic M, Stöhr T. Carboxylesterase 1-Based Drug-Drug Interaction Potential of Remimazolam: In-Vitro Studies and Literature Review. Curr Drug Metab. 2024 Aug 6.
Epub ahead of print
https://pubmed.ncbi.nlm.nih.gov/39108117/
https://pubmed.ncbi.nlm.nih.gov/38523539/
In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523.
Eur J Pharmacol. 2020 Mar 15;871:172934
https://pubmed.ncbi.nlm.nih.gov/31954706/
Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system.
Drug Des Devel Ther 13: 1033-1047 (2019)
https://www.dovepress.com/getfile.php?fileID=48858
How to conduct forced degradation studies – Scope and regulatory requirements.
Part 1: Pharm. Ind. 2019 (81), 1192-1196; Part 2: Pharm. Ind. 2019 (81), 1401-1409; Part 3: Pharm. Ind. 2020 (82), 55-61.
https://www.ecv.de/suse_search.php?suseMode=word&suseCookie=iv7c5cp6v0h9d05oo3o322c1d7&suseWord=How+to+conduct+forced+degradation+studies+
„Unerwartet“ verunreinigt – Eine kritische Betrachtung anlässlich einer neuen Meldung zu NDMA in Pioglitazon, Dtsch. Apoth. Ztg. 2019 (20), 50-58.
https://www.deutsche-apotheker-zeitung.de/daz-az/2019/daz-20-2019/unerwartet-verunreinigt
Investigation of TRPV1 loss-of-function phenotypes in TRPV1 Leu206Stop mice generated by N-ethyl-N-nitrosourea mutagenesis.
Biochem Biophys Res Commun. (2018) 500:456-461. https://pubmed.ncbi.nlm.nih.gov/29660342/?from_single_result=29660342
https://www.ncbi.nlm.nih.gov/pubmed/?term=Pepsin+and+its+importance+for+functional+dyspepsia
NDMA in Valsartan – Eine Spurensuche, 2018 (29), 22ff.
https://www.deutsche-apotheker-zeitung.de/daz-az/2018/daz-29-2018/ndma-in-valsartan
Analgetika der WHO-Stufe 1 zur Behandlung von (Migräne-) Kopfschmerzen.
WHO step 1 analgesics in the treatment of (migraine) headache.
Pharmakon 5, 69-74 (2017).
www.ingentaconnect.com/contentone/govi/pmakon/2017/00000005/00000001/art00010
https://www.researchgate.net/publication/311519102_Constipation_in_older_people_A_consensus_statement
https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00183
Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis: A Case Study with Two Structurally Related Diamines in Development.
Mol Pharm. 2017 Dec 4;14(12):4362-4373
https://www.ncbi.nlm.nih.gov/pubmed/?term=29099189
PPI in der Offizin.
Sicherer Umgang mit nicht rezeptpflichtigen Protonenpumpenhemmern.
Dustri-Verlag Karl Feistle, München-Deisenhofen (2016).
www.amazon.de/PPI-Offizin-Sicherer-rezeptpflichtigen-Protonenpumpenhemmern/dp/387185509X
Rezeptfrei erhältliche Schmerzmittel.
Intensiv- und Notfallbehandlung 40 (Suppl): S1-S27 (2015).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079111/
https://www.jgld.ro/jgld/index.php/jgld/article/view/2985
Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC-MS/MS.
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15;981-982:40-7.
https://www.ncbi.nlm.nih.gov/pubmed/?term=25600054
Burrowing as a non-reflex behavioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation.
Eur J Pain (2014) 18:204-12.
https://pubmed.ncbi.nlm.nih.gov/23853119/?from_single_result=23853119
Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs.
Vet Anaesth Analg. 2014 May;41(3):297-304.
https://www.ncbi.nlm.nih.gov/pubmed/?term=24576316
The case of drug causation of childhood asthma: antibiotics and paracetamol.
Eur J Clin Pharmacol. (2013 Jun); 69(6):1197-209. doi: 10.1007/s00228-012-1463-7. Epub 2013 Jan 5
www.ncbi.nlm.nih.gov/pmc/articles/PMC3651816
[Effectiveness of analgesic combinations in the self-medication.] Fixe Analgetika-Kombinationen, Viel besser als ihr Ruf?
MMW Fortschritte der Medizin (2013) 155(9):49-51.
link.springer.com/article/10.1007/s15223-014-0429-2
Spinal-supraspinal and intrinsic µ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
J Pharmacol Exp Ther (2013) 347:794-801.
https://pubmed.ncbi.nlm.nih.gov/24051022/?from_single_result=24051022
Tapentadol-from morphine and tramadol to the discovery of tapentadol.
Edited by: Fischer, J.; Ganellin, C.R.; Rotella, D.P
Analogue-Based Drug Discovery III (2013), 295-318.
onlinelibrary.wiley.com/doi/10.1002/9783527651085.ch12/summary
Comparative pharmacokinetics and bioavailability of tapentadol following oral administration
of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013 Apr;51(4):338-48.
https://www.ncbi.nlm.nih.gov/pubmed/?term=23357834
Mechanistic and functional differentiation of tapentadol and tramadol.
Expert Opinion on Pharmacotherapy (2012), 13(10), 1437-1449.
www.ncbi.nlm.nih.gov/pubmed/22698264
Pharmacological targeting of the thrombomodulin–protein C pathway mitigates radiation toxicity.
Nature Med 18: 1123-1129 (2012).
www.ncbi.nlm.nih.gov/pmc/articles/PMC3491776/
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study.
Nephron Extra. (2012 Jan); 2(1):104-14.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3383235
Paracetamol – ein moderner Klassiker unter falschem Verdacht [Acetaminophen – A modern classic under suspicion]
MMW-Fortschritte der Medizin (2011), 153, 128-136
publications.rwth-aachen.de/record/232788
Paracetamol: altbewährt oder riskant?
Deutsche Apotheker Zeitung (2011) 151(7): 68-72.
www.deutsche-apotheker-zeitung.de/daz-az/2011/daz-7-2011/paracetamol-altbewaehrt-oder-riskant
PIOfix-Study: Effects of Pioglitazone/Metformin fixed combination in comparison to a combination of Metformin with Glimepiride on diabetic dyslipidemia.
Diabetes Technol Ther. (2011 Jun);13(6):637-43.
www.ncbi.nlm.nih.gov/pubmed/21457065
C-Peptide and Intima Media Thickness in Type 2 Diabetes Mellitus Treated with Pioglitazone.
Diabetes Stoffw Herz (2011) 20: 65 – 68.
www.researchgate.net/publication/287414313_C-Peptide_and_Intima_Media_Thickness_in_Type_2_Diabetes_Mellitus_Treated_with_Pioglitazone
Pharmakokinetische Interaktionen und ihre Beurteilung. Klinische Betrachtungen zur Relevanz von Interaktionen der Protonenpumpenhemmer Omeprazol und Pantoprazol in der Selbstmedikation.
Med Monatsschr Pharm 34: 270-278 (2011).
www.medmopharm.de/archiv/verzeichnis/2011/08.html
Paracetamol und die Leber. Schäden bei zugelassenen Dosen?
Münchener Med Wochenschr – Fortschr Med 153: 137–142 (2011).
www.springermedizin.de/paracetamol-und-die-leber/10319378
Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.
Horm Metab Res. (2011 Dec) 43(13):980-3.
www.ncbi.nlm.nih.gov/pubmed/22068809
Tallarida RJ.
Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
J Pharmacol Exp Ther. 2011 Apr;337(1):312-20.
https://www.ncbi.nlm.nih.gov/pubmed/?term=21262850
Hörschäden durch Analgetika: ein neues Problem?
Deutsche Apotheker Zeitung (2010) 150: 66-70.
www.deutsche-apotheker-zeitung.de/daz-az/2010/daz-10-2010/hoerschaeden-durch-analgetika-ein-neues-problem
Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonen¬pumpeninhibitoren (PPIs). Positionspapier der Deutschen Gesellschaft für Verdauungs- und Stoff¬wechsel-krankheiten (DGVS) und der Deutschen Gesellschaft für Kardiologie (DGK).
Kardiologe 4: 353-364 (2010) and Z Gastroenterol 48: 1-8 (2010).
leitlinien.dgk.org/files/2010_Positionspapier_Thrombozytenaggregationshemmer_Protonenpumpeninhibitoren_PPI.pdf
Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
Clin Pharmacokinet. 2010 Oct;49(10):671-82.
https://www.ncbi.nlm.nih.gov/pubmed/?term=20818833
In vitro and in vivo characterization of tapentadol metabolites.
Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):31-8.
https://www.ncbi.nlm.nih.gov/pubmed/?term=20383344
Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
Pharmacotherapy. 2010 Jan;30(1):25-34.
https://www.ncbi.nlm.nih.gov/pubmed/?term=20030470
Diskussion um sichere Paracetamol-Dosierung.
Deutsche Apotheker Zeitung (2008) 148: 64-70.
www.deutsche-apotheker-zeitung.de/daz-az/2008/daz-29-2008/diskussion-um-sichere-paracetamol-dosierung
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Diabetes Vasc Dis Res (2008) 5:298–303.
dvr.sagepub.com/content/5/4/298.long
Pharmacokinetics of intravenous tramadol in dogs.
Can J Vet Res. 2008 Jul;72(4):325-31.
https://www.ncbi.nlm.nih.gov/pubmed/?term=18783021
Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes.
Drug Metab Lett. 2008 Jan;2(1):67-75.
https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073
Pharmaka mit Wirkungen auf den Gastrointestinaltrakt.
Pharmakologie und Toxikologie, Ed. Estler CJ.
Schattauer Verlag, Stuttgart; p. 597 – 636; 6. Ed. (2007).
Analgesics and Antipyretics
In: Ullmann’s Encyclopedia of Industrial Chemistry
Wiley-VHC, Weinheim, p 1-97 (2007).
onlinelibrary.wiley.com/doi/10.1002/14356007.a02_269.pub3/abstract
Absorption, Metabolism, and Excretion of 14C-Labeled Tapentadol HCl in Healthy Male Subjects.
Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep; 32(3):163-9.
www.ncbi.nlm.nih.gov/pubmed/18062408
Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Contraception. 2006 Sep;74(3):239-44.
https://pubmed.ncbi.nlm.nih.gov/16904418/?from_single_result=16904418
Multivariate analysis of nuclear magnetic resonance data – characterization of critical drug substance quality of gentamicin sulphate.
J Pharm Biomed. Anal. (2005) 38: 833-839.
www.ncbi.nlm.nih.gov/pubmed/16087045
A double-blind, placebo controlled trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Soy phospholipids and fiber enhance the cholesterol-lowering effect of soy protein.
European J. of Nutrition (2005) 44 (2): 65-71.
www.researchgate.net/publication/8402722_A_double-blind_placebo-controlled_clinical_trial_compares_the_cholesterollowering_effects_of_two_different_soy_protein_preparations_in_hypercholesterolemic_subjects
Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty. A randomised, placebo-controlled trial.
Clin Drug Invest 25 (2005) 89-97.
www.ncbi.nlm.nih.gov/pubmed/17523758
Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.
J Virol. (2005) 79: 9320-9324
www.ncbi.nlm.nih.gov/pmc/articles/PMC1168760
Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Curr Med Res Opin 20 (2004) 597-602.
www.ncbi.nlm.nih.gov/pubmed/15140325
Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review.
Advanced Therapeutics (2003) 20 (1): 50-78.
www.ncbi.nlm.nih.gov/pubmed/12772818
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Aliment Pharmacol Ther. 18 (2003) 615-25.
onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01695.x/abstract;jsessionid=BAFC6847E84C0900B421C681B676EF09.f04t01
Analgesics – In: Chemistry & Pharmacology to Clinical Application.
604 pages, Wiley-VCH, ISBN 3-527-30403-7, (2002).
Interferon regulatory factor-3 is an in vivo target of DNA-PK.
Proc Natl Acad Sci USA. (2002) 99: 2818-2823.
www.ncbi.nlm.nih.gov/pmc/articles/PMC122431
Anxiolytic-like effects of Kava-Kava in the elevated plus maze test-a comparison with diazepam.
Progress of Pharmacology and Toxicology, 26 (2002) 26: 855-860.
www.ncbi.nlm.nih.gov/pubmed/12369257
Ergebnisse zur pharmakologischen Untersuchung von Substanzen im Modell der physiologischen ex vivo-Hämoperfusion der isolierten Niere, pp 451-452. In: Forschung ohne Tierversuche 2000,
Schöffl H, Spielmann H, Gruber FP, Appl H, Harrer F, Pfaller W, Tritthart HA. Ersatz und Ergänzungsmethoden zu Tierversuchen, Ed. H. Schöffl, H. Spielmann und H. A. Tritthart. Springer-Verlag Wien, New York (2000).
www.researchgate.net/publication/300046134_Erste_Ergebnisse_zur_pharmakologischen_Untersuchung_von_Substanzen_im_Modell_der_physiologischen_ex_vivo-_Hamoperfusion_der_isolierten_Niere
Characterization of a novel serine/threonine kinase associated with nuclear bodies.
J Biol Chem (2000) 275: 7373-7377.
www.jbc.org/content/275/10/7373.long
Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration.
Br J Anaesth. 2000 Mar;84(3):346-9.
https://pubmed.ncbi.nlm.nih.gov/10793594/?from_single_result=10793594
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol).
Arzneimittelforschung. 2000 Feb;50(2):99-108.
https://pubmed.ncbi.nlm.nih.gov/10719611/?from_single_result=10719611
Die antiphlogistische Wirkung von Bronchipret¨ und seiner Komponenten im Rattenpfoten-ödem-Modell. In: Bronchitis – Neue Erkenntnisse zu Wirkungen und Wirksamkeit von Arzneipflanzen.
Ed. R.W. März
Karger Verlag, Freiburg, 1-9 (1998)
Enantioselective Inhibition of TNF-a Release by Thalidomide and Thalidomide-Analogues.
Chirality (1996) 8: 390-396.
www.ncbi.nlm.nih.gov/pubmed/8900028
The beagle dog as a predictor of gastrointestinal findings in humans caused by the prostacyclin analogue taprostene.
Exp Toxic Pathol. (1994) 46: 71-73.
www.ncbi.nlm.nih.gov/pubmed/8086790
Thalidomide enantiomers.
The Lancet (1992) 339: 365.
www.ncbi.nlm.nih.gov/pubmed/1346437
Computer Aided Protein Design: Three Dimensional Model Building of the Saruplase Structure.
in Supercomputer and Chemistry 2, U. Harms (Ed.),
Springer-Verlag Berlin Heidelberg, (1991) S. 159-166.
link.springer.com/chapter/10.1007/978-3-642-50175-3_12
Naxaprostene.
Drugs of the Future (1990) 15: 233-236.
https://pubmed.ncbi.nlm.nih.gov/39108117/
Schmalix W, Petersen KU, Pesic M, Stöhr T. The Metabolism of the New Benzodiazepine Remimazolam. Curr Drug Metab. 25: 164-173 (2024)
https://pubmed.ncbi.nlm.nih.gov/38523539/
Damann N, Bahrenberg G, Stockhausen H, Habermann CJ, Lesch B, Frank-Foltyn R, Lee J, Ann J, Christoph T.
In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523.
Eur J Pharmacol. 2020 Mar 15;871:172934
https://pubmed.ncbi.nlm.nih.gov/31954706/
Freyer N, Knöspel F, Damm G, Greuel S, Schneider C, Seehofer D, Stöhr T, Petersen KU, Zeilinger K.
Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system.
Drug Des Devel Ther 13: 1033-1047 (2019)
https://www.dovepress.com/getfile.php?fileID=48858
Buschmann H, Handler N
How to conduct forced degradation studies – Scope and regulatory requirements.
Part 1: Pharm. Ind. 2019 (81), 1192-1196; Part 2: Pharm. Ind. 2019 (81), 1401-1409; Part 3: Pharm. Ind. 2020 (82), 55-61.
https://www.ecv.de/suse_search.php?suseMode=word&suseCookie=iv7c5cp6v0h9d05oo3o322c1d7&suseWord=How+to+conduct+forced+degradation+studies+
Buschmann H, Holzgrabe U, Jung D.
„Unerwartet“ verunreinigt – Eine kritische Betrachtung anlässlich einer neuen Meldung zu NDMA in Pioglitazon, Dtsch. Apoth. Ztg. 2019 (20), 50-58.
https://www.deutsche-apotheker-zeitung.de/daz-az/2019/daz-20-2019/unerwartet-verunreinigt
Christoph T, Kögel B, Schiene K, Peters T, Schröder W.
Investigation of TRPV1 loss-of-function phenotypes in TRPV1 Leu206Stop mice generated by N-ethyl-N-nitrosourea mutagenesis.
Biochem Biophys Res Commun. (2018) 500:456-461. https://pubmed.ncbi.nlm.nih.gov/29660342/?from_single_result=29660342
Petersen KU. Pepsin and its importance for functional dyspepsia: Relic, regulator or remedy? Dig Sci 36: 98-105 (2018)
https://www.ncbi.nlm.nih.gov/pubmed/?term=Pepsin+and+its+importance+for+functional+dyspepsia
Christoph T, Raffa R, De Vry J, Schröder W.
Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.
Pharmacol Res Perspect. (2018) 6(6):e00444. doi: 10.1002/prp2.444. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6262002/
Buschmann H, Holzgrabe U Dtsch. Apoth. Ztg.
NDMA in Valsartan – Eine Spurensuche, 2018 (29), 22ff.
https://www.deutsche-apotheker-zeitung.de/daz-az/2018/daz-29-2018/ndma-in-valsartan
Handler N, Buschmann H.
Drug Selectivity: An Evolving Concept in Medicinal Chemistry, Wiley-VCH, 520 pages, ISBN-10: 3527335382 (2018).
https://doi.org/10.1002/cmdc.201800493
Petersen KU, Kops M, Heintze K.
Analgetika der WHO-Stufe 1 zur Behandlung von (Migräne-) Kopfschmerzen.
WHO step 1 analgesics in the treatment of (migraine) headache.
Pharmakon 5, 69-74 (2017).
www.ingentaconnect.com/contentone/govi/pmakon/2017/00000005/00000001/art00010
Emmanuel A, Mattace-Raso F, Neri MC, Petersen KU, Rey E, Rogers J. Constipation in older people: A consensus statement. Int J Clin Pract. 71(1) (2017)
https://www.researchgate.net/publication/311519102_Constipation_in_older_people_A_consensus_statement
Carta, F. Birkmann, A., Pfaff, T., Buschmann, H., Schwab, W. Zimmermann, H., Maresca, A., Supuran, C. T. (2017): Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action. J. Med. Chem., 60, 3154−3164.
https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00183
Loryan I, Hoppe E, Hansen K, Held F, Kless A, Linz K, Marossek V, Nolte B, Ratcliffe P, Saunders D, Terlinden R, Wegert A, Welbers A, Will O, Hammarlund-Udenaes M.
Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis: A Case Study with Two Structurally Related Diamines in Development.
Mol Pharm. 2017 Dec 4;14(12):4362-4373
https://www.ncbi.nlm.nih.gov/pubmed/?term=29099189
Klotz U, Koop H, Labenz J, Petersen KU (Petersen KU, Hrsg.).
PPI in der Offizin.
Sicherer Umgang mit nicht rezeptpflichtigen Protonenpumpenhemmern.
Dustri-Verlag Karl Feistle, München-Deisenhofen (2016).
www.amazon.de/PPI-Offizin-Sicherer-rezeptpflichtigen-Protonenpumpenhemmern/dp/387185509X
Petersen KU.
Rezeptfrei erhältliche Schmerzmittel.
Intensiv- und Notfallbehandlung 40 (Suppl): S1-S27 (2015).
Lohmer LL, Schippers F, Petersen KU, Stoehr T, Schmith VD. Time-to-event modeling for remimazolam for the indication of induction and maintenance of general anesthesia. J Clin Pharmacol 60: 505-514 (2020)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079111/
Petersen KU, Malfertheiner P, Mössner J. The Role of sphere size in the context of pancreatin therapy for exocrine pancreatic insufficiency: A systematic review. J Gastrointestin Liver Dis 30: 132-141 (2021)
https://www.jgld.ro/jgld/index.php/jgld/article/view/2985
Kops MS, Pesic M, Petersen KU, Schmalix WA, Stöhr T. Impact of concurrent remifentanil on the sedative effects of remimazolam, midazolam and propofol in cynomolgus monkeys. Eur J Pharmacol 890 (2021) 173639 (2021)
Hillewaert V, Pusecker K, Sips L, Verhaeghe T, de Vries R, Langhans M, Terlinden R, Timmerman P.
Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC-MS/MS.
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15;981-982:40-7.
https://www.ncbi.nlm.nih.gov/pubmed/?term=25600054
Rutten K, Schiene K, Robens A, Leipelt A, Pasqualon T, Read SJ, Christoph T.
Burrowing as a non-reflex behavioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation.
Eur J Pain (2014) 18:204-12.
https://pubmed.ncbi.nlm.nih.gov/23853119/?from_single_result=23853119
Kögel B, Terlinden R, Schneider J.
Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs.
Vet Anaesth Analg. 2014 May;41(3):297-304.
https://www.ncbi.nlm.nih.gov/pubmed/?term=24576316
Heintze K, Petersen KU.
The case of drug causation of childhood asthma: antibiotics and paracetamol.
Eur J Clin Pharmacol. (2013 Jun); 69(6):1197-209. doi: 10.1007/s00228-012-1463-7. Epub 2013 Jan 5
www.ncbi.nlm.nih.gov/pmc/articles/PMC3651816
Morgenstern ECA, Heintze K.
[Effectiveness of analgesic combinations in the self-medication.] Fixe Analgetika-Kombinationen, Viel besser als ihr Ruf?
MMW Fortschritte der Medizin (2013) 155(9):49-51.
link.springer.com/article/10.1007/s15223-014-0429-2
Christoph T, Schröder W, Tallarida RT, De Vry J, Tzschentke TM.
Spinal-supraspinal and intrinsic µ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
J Pharmacol Exp Ther (2013) 347:794-801.
https://pubmed.ncbi.nlm.nih.gov/24051022/?from_single_result=24051022
Buschmann H.
Tapentadol-from morphine and tramadol to the discovery of tapentadol.
Edited by: Fischer, J.; Ganellin, C.R.; Rotella, D.P
Analogue-Based Drug Discovery III (2013), 295-318.
onlinelibrary.wiley.com/doi/10.1002/9783527651085.ch12/summary
Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R.
Comparative pharmacokinetics and bioavailability of tapentadol following oral administration
of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013 Apr;51(4):338-48.
https://www.ncbi.nlm.nih.gov/pubmed/?term=23357834
Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Koegel B, Schiene K, Strassburger W, et al.
Mechanistic and functional differentiation of tapentadol and tramadol.
Expert Opinion on Pharmacotherapy (2012), 13(10), 1437-1449.
www.ncbi.nlm.nih.gov/pubmed/22698264
Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Fernández JA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C. Weiler H, Hauer-Jensen M.
Pharmacological targeting of the thrombomodulin–protein C pathway mitigates radiation toxicity.
Nature Med 18: 1123-1129 (2012).
www.ncbi.nlm.nih.gov/pmc/articles/PMC3491776/
Galle J, Kleophas W, Dellanna F, Schmid VH, Forkel C, Dikta G, Krajewski V, Fuchs W, Forst T, Pfützner A.
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study.
Nephron Extra. (2012 Jan); 2(1):104-14.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3383235
Buschmann H, Heintze K, Morgenstern E.
Paracetamol – ein moderner Klassiker unter falschem Verdacht [Acetaminophen – A modern classic under suspicion]
MMW-Fortschritte der Medizin (2011), 153, 128-136
publications.rwth-aachen.de/record/232788
Kops M, Paulus W, Heintze K, Petersen KU.
Paracetamol: altbewährt oder riskant?
Deutsche Apotheker Zeitung (2011) 151(7): 68-72.
www.deutsche-apotheker-zeitung.de/daz-az/2011/daz-7-2011/paracetamol-altbewaehrt-oder-riskant
Pfützner A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, Müller J, Lehmann U, Fuchs W, Forst T.
PIOfix-Study: Effects of Pioglitazone/Metformin fixed combination in comparison to a combination of Metformin with Glimepiride on diabetic dyslipidemia.
Diabetes Technol Ther. (2011 Jun);13(6):637-43.
www.ncbi.nlm.nih.gov/pubmed/21457065
Forst T, Weber M, Pfützner A, Kleine I, Löbig M, Hohberg C, Fuchs W.
C-Peptide and Intima Media Thickness in Type 2 Diabetes Mellitus Treated with Pioglitazone.
Diabetes Stoffw Herz (2011) 20: 65 – 68.
www.researchgate.net/publication/287414313_C-Peptide_and_Intima_Media_Thickness_in_Type_2_Diabetes_Mellitus_Treated_with_Pioglitazone
Petersen KU.
Pharmakokinetische Interaktionen und ihre Beurteilung. Klinische Betrachtungen zur Relevanz von Interaktionen der Protonenpumpenhemmer Omeprazol und Pantoprazol in der Selbstmedikation.
Med Monatsschr Pharm 34: 270-278 (2011).
www.medmopharm.de/archiv/verzeichnis/2011/08.html
Petersen KU.
Paracetamol und die Leber. Schäden bei zugelassenen Dosen?
Münchener Med Wochenschr – Fortschr Med 153: 137–142 (2011).
www.springermedizin.de/paracetamol-und-die-leber/10319378
Hanefeld M, Schaper F, Appelt D, Fuchs W.
Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.
Horm Metab Res. (2011 Dec) 43(13):980-3.
www.ncbi.nlm.nih.gov/pubmed/22068809
Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T,
Tallarida RJ.
Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
J Pharmacol Exp Ther. 2011 Apr;337(1):312-20.
https://www.ncbi.nlm.nih.gov/pubmed/?term=21262850
Heintze K.
Hörschäden durch Analgetika: ein neues Problem?
Deutsche Apotheker Zeitung (2010) 150: 66-70.
www.deutsche-apotheker-zeitung.de/daz-az/2010/daz-10-2010/hoerschaeden-durch-analgetika-ein-neues-problem
Fischbach W, Darius H, Gross M, Koop H, Kruck I, Petersen KU.
Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonen¬pumpeninhibitoren (PPIs). Positionspapier der Deutschen Gesellschaft für Verdauungs- und Stoff¬wechsel-krankheiten (DGVS) und der Deutschen Gesellschaft für Kardiologie (DGK).
Kardiologe 4: 353-364 (2010) and Z Gastroenterol 48: 1-8 (2010).
leitlinien.dgk.org/files/2010_Positionspapier_Thrombozytenaggregationshemmer_Protonenpumpeninhibitoren_PPI.pdf
Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P.
Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
Clin Pharmacokinet. 2010 Oct;49(10):671-82.
https://www.ncbi.nlm.nih.gov/pubmed/?term=20818833
Terlinden R, Kogel BY, Englberger W, Tzschentke TM.
In vitro and in vivo characterization of tapentadol metabolites.
Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):31-8.
https://www.ncbi.nlm.nih.gov/pubmed/?term=20383344
Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, Upmalis D, Mangold B.
Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
Pharmacotherapy. 2010 Jan;30(1):25-34.
https://www.ncbi.nlm.nih.gov/pubmed/?term=20030470
Heintze K.
Diskussion um sichere Paracetamol-Dosierung.
Deutsche Apotheker Zeitung (2008) 148: 64-70.
www.deutsche-apotheker-zeitung.de/daz-az/2008/daz-29-2008/diskussion-um-sichere-paracetamol-dosierung
Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M.
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Diabetes Vasc Dis Res (2008) 5:298–303.
dvr.sagepub.com/content/5/4/298.long
McMillan CJ, Livingston A, Clark CR, Dowling PM, Taylor SM, Duke T, Terlinden R.
Pharmacokinetics of intravenous tramadol in dogs.
Can J Vet Res. 2008 Jul;72(4):325-31.
https://www.ncbi.nlm.nih.gov/pubmed/?term=18783021
Kneip C, Terlinden R, Beier H, Chen G.
Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes.
Drug Metab Lett. 2008 Jan;2(1):67-75.
https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073
Petersen KU, Labens J, Heintze K.
Pharmaka mit Wirkungen auf den Gastrointestinaltrakt.
Pharmakologie und Toxikologie, Ed. Estler CJ.
Schattauer Verlag, Stuttgart; p. 597 – 636; 6. Ed. (2007).
Friderichs E, Christoph T, Buschmann H.
Analgesics and Antipyretics
In: Ullmann’s Encyclopedia of Industrial Chemistry
Wiley-VHC, Weinheim, p 1-97 (2007).
onlinelibrary.wiley.com/doi/10.1002/14356007.a02_269.pub3/abstract
Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K.
Absorption, Metabolism, and Excretion of 14C-Labeled Tapentadol HCl in Healthy Male Subjects.
Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep; 32(3):163-9.
www.ncbi.nlm.nih.gov/pubmed/18062408
Terlinden R, Uragg H, Göhler K, Kneip C.
Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Contraception. 2006 Sep;74(3):239-44.
https://pubmed.ncbi.nlm.nih.gov/16904418/?from_single_result=16904418
Winter W, Deubner R, Holzgrabe U.
Multivariate analysis of nuclear magnetic resonance data – characterization of critical drug substance quality of gentamicin sulphate.
J Pharm Biomed. Anal. (2005) 38: 833-839.
www.ncbi.nlm.nih.gov/pubmed/16087045
Hoie, LH, Morgenstern ECA., Gruenwald J., Graubaum H-J, Busch R, Lüder W, Zunft H-JF.
A double-blind, placebo controlled trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Soy phospholipids and fiber enhance the cholesterol-lowering effect of soy protein.
European J. of Nutrition (2005) 44 (2): 65-71.
www.researchgate.net/publication/8402722_A_double-blind_placebo-controlled_clinical_trial_compares_the_cholesterollowering_effects_of_two_different_soy_protein_preparations_in_hypercholesterolemic_subjects
Schindler C, Schweizer J, Müller A, Koch R, Hellner G, Fuchs W, Kirch W.
Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty. A randomised, placebo-controlled trial.
Clin Drug Invest 25 (2005) 89-97.
www.ncbi.nlm.nih.gov/pubmed/17523758
Kirshner, JR, Karpova, AY, Kops M, Howley PM.
Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.
J Virol. (2005) 79: 9320-9324
www.ncbi.nlm.nih.gov/pmc/articles/PMC1168760
Bönner G, Fuchs W.
Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Curr Med Res Opin 20 (2004) 597-602.
www.ncbi.nlm.nih.gov/pubmed/15140325
Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J.
Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review.
Advanced Therapeutics (2003) 20 (1): 50-78.
www.ncbi.nlm.nih.gov/pubmed/12772818
Malfertheiner P, Mössner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, Fuchs W.
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Aliment Pharmacol Ther. 18 (2003) 615-25.
onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01695.x/abstract;jsessionid=BAFC6847E84C0900B421C681B676EF09.f04t01
Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B.
Analgesics – In: Chemistry & Pharmacology to Clinical Application.
604 pages, Wiley-VCH, ISBN 3-527-30403-7, (2002).
Karpova AY, Trost M, Murray JM, Cantley LC, Howley PM.
Interferon regulatory factor-3 is an in vivo target of DNA-PK.
Proc Natl Acad Sci USA. (2002) 99: 2818-2823.
www.ncbi.nlm.nih.gov/pmc/articles/PMC122431
Rex A, Morgenstern E, Fink H.
Anxiolytic-like effects of Kava-Kava in the elevated plus maze test-a comparison with diazepam.
Progress of Pharmacology and Toxicology, 26 (2002) 26: 855-860.
www.ncbi.nlm.nih.gov/pubmed/12369257
Morgenstern, E, Stattmann A, Grosse-Siestrup C, Stahl K, von Bayer H.
Ergebnisse zur pharmakologischen Untersuchung von Substanzen im Modell der physiologischen ex vivo-Hämoperfusion der isolierten Niere, pp 451-452. In: Forschung ohne Tierversuche 2000,
Schöffl H, Spielmann H, Gruber FP, Appl H, Harrer F, Pfaller W, Tritthart HA. Ersatz und Ergänzungsmethoden zu Tierversuchen, Ed. H. Schöffl, H. Spielmann und H. A. Tritthart. Springer-Verlag Wien, New York (2000).
www.researchgate.net/publication/300046134_Erste_Ergebnisse_zur_pharmakologischen_Untersuchung_von_Substanzen_im_Modell_der_physiologischen_ex_vivo-_Hamoperfusion_der_isolierten_Niere
Trost M, Kochs G, Haller O.
Characterization of a novel serine/threonine kinase associated with nuclear bodies.
J Biol Chem (2000) 275: 7373-7377.
www.jbc.org/content/275/10/7373.long
Murthy BV, Pandya KS, Booker PD, Murray A, Lintz W, Terlinden R.
Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration.
Br J Anaesth. 2000 Mar;84(3):346-9.
https://pubmed.ncbi.nlm.nih.gov/10793594/?from_single_result=10793594
Lintz W, Becker R, Gerloff J, Terlinden R.
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol).
Arzneimittelforschung. 2000 Feb;50(2):99-108.
https://pubmed.ncbi.nlm.nih.gov/10719611/?from_single_result=10719611
Morgenstern, E.
Die antiphlogistische Wirkung von Bronchipret¨ und seiner Komponenten im Rattenpfoten-ödem-Modell. In: Bronchitis – Neue Erkenntnisse zu Wirkungen und Wirksamkeit von Arzneipflanzen.
Ed. R.W. März
Karger Verlag, Freiburg, 1-9 (1998)
Wnendt S, Finkam M, Winter W, Ossig J, Raabe G and Zwingenberger K.
Enantioselective Inhibition of TNF-a Release by Thalidomide and Thalidomide-Analogues.
Chirality (1996) 8: 390-396.
www.ncbi.nlm.nih.gov/pubmed/8900028
Wöhrmann T, Kögel B-Y, Schneider J, Matthiesen T.
The beagle dog as a predictor of gastrointestinal findings in humans caused by the prostacyclin analogue taprostene.
Exp Toxic Pathol. (1994) 46: 71-73.
www.ncbi.nlm.nih.gov/pubmed/8086790
Winter W, Frankus E.
Thalidomide enantiomers.
The Lancet (1992) 339: 365.
www.ncbi.nlm.nih.gov/pubmed/1346437
Straßburger W, Winter W, Steffens GJ, Günzler WA and Flohé L.
Computer Aided Protein Design: Three Dimensional Model Building of the Saruplase Structure.
in Supercomputer and Chemistry 2, U. Harms (Ed.),
Springer-Verlag Berlin Heidelberg, (1991) S. 159-166.
link.springer.com/chapter/10.1007/978-3-642-50175-3_12
Winter W.
Naxaprostene.
Drugs of the Future (1990) 15: 233-236.